In tumor immune responses, CD4+ T cells can activate CD8+ T cells through a variety of mechanisms, so that CD8+ T cells can differentiate into cytotoxic T lymphocytes while maintaining and strengthening the antitumor response. The gene discussed is CD8A; the disease is neoplasm.